Health Care · Biotechnology
Gilead Sciences: revenue, profit and dividends
In fiscal 2025, Gilead Sciences had revenue of $29.4B, down 1.0% a year on average since 2015, and net income of $8.51B (28.9% of revenue). Its dividend per share has gone up 10 years in a row, to $3.16. It has 17% fewer shares than in 2015.
Revenue, fiscal 2025
average annual revenue growth since 2015 · +2.4% vs 2024
- Ticker
- GILD · Nasdaq
- Sector
- Health Care
- Sub-industry
- Biotechnology
- Headquarters
- Foster City, California
- Founded
- 1987
- In the S&P 500 since
- July 1, 2004
- Latest fiscal year
- 2025, ended December 31, 2025
- SEC filer
- Gilead Sciences, Inc. · CIK 0000882095
Revenue and net income
Revenue went from $4.23B in 2007 to $29.4B in 2025.
Diluted earnings per share
Diluted EPS went from $0.82 in 2007 to $6.78 in 2025. Ten-year growth: −5.5% a year.
Dividends per share
Raised 10 years in a row, every year from 2016 to 2025. Ten-year growth: 9.4% a year.
Shares outstanding
17.5% fewer shares in 2025 than in 2015 (1.52B → 1.25B): buybacks outweighed new shares.
Operating cash flow, capex and free cash flow
Free cash flow (operating cash flow minus capital expenditure) was $9.46B in 2025, 32.1% of revenue.
The chart data could not be loaded. The table below has the same figures.
Year by year
| Fiscal year | Revenue | Net income | Net margin | Diluted EPS | Dividend | Shares | Operating cash flow | Capex | Free cash flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | $29.4B | $8.51B | 28.9% | $6.78 | $3.16 | 1.25B | $10B | $563M | $9.46B |
| 2024 | $28.8B | $480M | 1.7% | $0.38 | $3.08 | 1.25B | $10.8B | $523M | $10.3B |
| 2023 | $27.1B | $5.67B | 20.9% | $4.50 | $3.00 | 1.26B | $8.01B | $585M | $7.42B |
| 2022 | $27.3B | $4.59B | 16.8% | $3.64 | $2.92 | 1.26B | $9.07B | $728M | $8.34B |
| 2021 | $27.3B | $6.22B | 22.8% | $4.93 | $2.84 | 1.26B | $11.4B | $579M | $10.8B |
| 2020 | $24.7B | $123M | 0.5% | $0.10 | $2.72 | 1.26B | $8.17B | $650M | $7.52B |
| 2019 | $22.4B | $5.39B | 24.0% | $4.22 | $2.52 | 1.28B | $9.14B | $825M | $8.32B |
| 2018 | $22.1B | $5.46B | 24.7% | $4.17 | $2.28 | 1.31B | $8.4B | $924M | $7.48B |
| 2017 | $26.1B | $4.63B | 17.7% | $3.51 | $2.08 | 1.32B | $11.9B | $590M | $11.3B |
| 2016 | $30.4B | $13.5B | 44.4% | $9.94 | $1.84 | 1.36B | $17B | $748M | $16.3B |
| 2015 | $32.6B | $18.1B | 55.5% | $11.91 | $1.29 | 1.52B | $21.2B | $747M | $20.5B |
| 2014 | $24.9B | $12.1B | 48.6% | $7.35 | $0.00 | 1.65B | $12.8B | $557M | $12.3B |
| 2013 | $11.2B | $3.08B | 27.5% | $1.81 | $0.00 | 1.7B | $3.1B | $134M | $2.97B |
| 2012 | $9.7B | $2.59B | 26.7% | $1.64 | — | 1.58B | $3.19B | $397M | $2.8B |
| 2011 | $8.39B | $2.8B | 33.4% | $1.77 | — | 1.58B | $3.64B | $132M | $3.51B |
| 2010 | $7.95B | $2.9B | 36.5% | $1.66 | — | 1.75B | $2.83B | $61.9M | $2.77B |
| 2009 | $7.01B | $2.64B | 37.6% | $1.41 | — | 1.87B | $3.08B | $230M | $2.85B |
| 2008 | $5.34B | $1.98B | 37.1% | $1.03 | — | 1.92B | $2.14B | $115M | $2.03B |
| 2007 | $4.23B | $1.58B | 37.5% | $0.82 | — | 1.93B | $1.67B | $78.6M | $1.59B |
Fiscal years, labelled by the year in which they end. US dollars; per-share figures and share counts adjusted for splits. —: not in the data.
Stock splits
Found in the filings; per-share figures and share counts on this page are on today’s share basis.
- 2-for-1 split · first reflected in a filing of February 27, 2013
About these figures
- Older years are as filed at the time and may predate later restatements, mergers or spin-offs. How the figures are made.
Other Biotechnology companies
Source: SEC EDGAR (company filings), data as of November 8, 2026. Sectors, sub-industries, headquarters and index dates: Wikipedia, CC BY-SA 4.0.